Due diligence of a biotech with a novel single chain antibody platform

Challenge: A European investor asked Alacrita to conduct a due diligence exercise on a company that had developed a novel single chain antibody platform with its lead product in ADC format ahead of a...
Learn More

Investor due diligence of a development-stage microbiome company

Due Diligence Challenge: An investor was considering re-investing into a development-stage microbiome company that had experienced certain issues that delayed timelines and changed the risk profile....
Learn More

Investor Due Diligence: Pharma Business Development Case Studies

Alacrita frequently works on behalf of investors to conduct due diligence on prospective transactions. The two case studies below offer a snapshot of the typical expertise we provide in this area. To...
Learn More

Due diligence: biologic technologies & phase III probability of success of CNS asset

Case Study 1, Challenge: A mid-size pharmaceutical company seeking opportunities to diversify within its core therapeutic area by partnering in products based on biologic technologies retained...
Learn More

Due diligence of a plasma protein manufacturer for a PE investor

Challenge: A private equity investor was considering a transaction in a company supplying therapeutic proteins derived from biological sources for the treatment of numerous diseases in the...
Learn More

Due diligence on a new medical imaging technology

Challenge: A well-capitalized Swiss pharma company needed a clinical and commercial reality check for a new imaging technology being developed that was under consideration for acquisition.
Learn More

Due diligence on a novel T cell therapy and discovery platform

Challenge: A VC investor wished to make an investment in a California-based preclinical biotechnology company with a discovery platform and novel T cell therapies for cancer and other diseases....
Learn More

Providing due diligence for a company developing R&D tools using pluripotent stem cells

Challenge: A UK-based VC wished to invest in a biotech spin-out focussed on the development of R&D tools using induced pluripotent stem cells (iPSCs) as organoids to mimic human tissues. These...
Learn More

Investor due diligence on preclinical stage vaccine platform technology

Challenge: Following a pre-due diligence exercise, an investment firm asked Alacrita to conduct a deeper due diligence on a biotech company's vaccine platform technology targeted towards infectious...
Learn More

Investor due diligence on clinical stage oncology therapeutic company

Challenge: A VC investor asked Alacrita to conduct due diligence on a clinical stage oncology therapeutic company developing a targeted inhibitor that works via the notch pathway. Priority...
Learn More

Due diligence for VC firm

Challenge: A government owned investment firm was considering an investment in a small biopharma company developing a therapeutic monoclonal antibody against a novel immuno-oncology target.  Alacrita...
Learn More

Providing reality checks on commercial opportunities

Challenge:  A transatlantic life science venture capital fund was contemplating investing in advanced plasma product opportunities being developed by a biopharmaceutical company, and needed a reality...
Learn More
Content not found